Cargando…
Implications of Glycosaminoglycans on Viral Zoonotic Diseases
Zoonotic diseases are infectious diseases that pass from animals to humans. These include diseases caused by viruses, bacteria, fungi, and parasites and can be transmitted through close contact or through an intermediate insect vector. Many of the world’s most problematic zoonotic diseases are viral...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628766/ https://www.ncbi.nlm.nih.gov/pubmed/34842642 http://dx.doi.org/10.3390/diseases9040085 |
_version_ | 1784607066147520512 |
---|---|
author | Bauer, Sarah Zhang, Fuming Linhardt, Robert J. |
author_facet | Bauer, Sarah Zhang, Fuming Linhardt, Robert J. |
author_sort | Bauer, Sarah |
collection | PubMed |
description | Zoonotic diseases are infectious diseases that pass from animals to humans. These include diseases caused by viruses, bacteria, fungi, and parasites and can be transmitted through close contact or through an intermediate insect vector. Many of the world’s most problematic zoonotic diseases are viral diseases originating from animal spillovers. The Spanish influenza pandemic, Ebola outbreaks in Africa, and the current SARS-CoV-2 pandemic are thought to have started with humans interacting closely with infected animals. As the human population grows and encroaches on more and more natural habitats, these incidents will only increase in frequency. Because of this trend, new treatments and prevention strategies are being explored. Glycosaminoglycans (GAGs) are complex linear polysaccharides that are ubiquitously present on the surfaces of most human and animal cells. In many infectious diseases, the interactions between GAGs and zoonotic pathogens correspond to the first contact that results in the infection of host cells. In recent years, researchers have made progress in understanding the extraordinary roles of GAGs in the pathogenesis of zoonotic diseases, suggesting potential therapeutic avenues for using GAGs in the treatment of these diseases. This review examines the role of GAGs in the progression, prevention, and treatment of different zoonotic diseases caused by viruses. |
format | Online Article Text |
id | pubmed-8628766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86287662021-11-30 Implications of Glycosaminoglycans on Viral Zoonotic Diseases Bauer, Sarah Zhang, Fuming Linhardt, Robert J. Diseases Review Zoonotic diseases are infectious diseases that pass from animals to humans. These include diseases caused by viruses, bacteria, fungi, and parasites and can be transmitted through close contact or through an intermediate insect vector. Many of the world’s most problematic zoonotic diseases are viral diseases originating from animal spillovers. The Spanish influenza pandemic, Ebola outbreaks in Africa, and the current SARS-CoV-2 pandemic are thought to have started with humans interacting closely with infected animals. As the human population grows and encroaches on more and more natural habitats, these incidents will only increase in frequency. Because of this trend, new treatments and prevention strategies are being explored. Glycosaminoglycans (GAGs) are complex linear polysaccharides that are ubiquitously present on the surfaces of most human and animal cells. In many infectious diseases, the interactions between GAGs and zoonotic pathogens correspond to the first contact that results in the infection of host cells. In recent years, researchers have made progress in understanding the extraordinary roles of GAGs in the pathogenesis of zoonotic diseases, suggesting potential therapeutic avenues for using GAGs in the treatment of these diseases. This review examines the role of GAGs in the progression, prevention, and treatment of different zoonotic diseases caused by viruses. MDPI 2021-11-17 /pmc/articles/PMC8628766/ /pubmed/34842642 http://dx.doi.org/10.3390/diseases9040085 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bauer, Sarah Zhang, Fuming Linhardt, Robert J. Implications of Glycosaminoglycans on Viral Zoonotic Diseases |
title | Implications of Glycosaminoglycans on Viral Zoonotic Diseases |
title_full | Implications of Glycosaminoglycans on Viral Zoonotic Diseases |
title_fullStr | Implications of Glycosaminoglycans on Viral Zoonotic Diseases |
title_full_unstemmed | Implications of Glycosaminoglycans on Viral Zoonotic Diseases |
title_short | Implications of Glycosaminoglycans on Viral Zoonotic Diseases |
title_sort | implications of glycosaminoglycans on viral zoonotic diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628766/ https://www.ncbi.nlm.nih.gov/pubmed/34842642 http://dx.doi.org/10.3390/diseases9040085 |
work_keys_str_mv | AT bauersarah implicationsofglycosaminoglycansonviralzoonoticdiseases AT zhangfuming implicationsofglycosaminoglycansonviralzoonoticdiseases AT linhardtrobertj implicationsofglycosaminoglycansonviralzoonoticdiseases |